Literature DB >> 18443809

[Methotrexate: advantages of subcutaneous administration].

K Krüger1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443809     DOI: 10.1007/s00393-008-0295-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  7 in total

1.  Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate.

Authors:  A Rozin; D Schapira; A Balbir-Gurman; Y Braun-Moscovici; D Markovits; D Militianu; M A Nahir
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

2.  Parenteral methotrexate should be given before biological therapy.

Authors:  S J Bingham; M H Buch; S Lindsay; A Pollard; J White; P Emery
Journal:  Rheumatology (Oxford)       Date:  2003-08       Impact factor: 7.580

Review 3.  Benefit and risk of methotrexate treatment in rheumatoid arthritis.

Authors:  R Rau; G Herborn
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

Review 4.  Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis.

Authors:  Bruce N Cronstein
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

5.  Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis.

Authors:  R A Hamilton; J M Kremer
Journal:  Br J Rheumatol       Date:  1997-01

6.  Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.

Authors:  Monique Hoekstra; Cees Haagsma; Cees Neef; Johannes Proost; Antonius Knuif; Mart van de Laar
Journal:  J Rheumatol       Date:  2004-04       Impact factor: 4.666

7.  Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis.

Authors:  J Wegrzyn; P Adeleine; P Miossec
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

  7 in total
  1 in total

1.  [Therapy of rheumatoid arthritis with methotrexate. Claims data analysis of treatment patterns].

Authors:  J Zeidler; H Zeidler; J-M Graf von der Schulenburg
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.